Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FER_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FER_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FER_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FER_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FER_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FER_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FER_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FER_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FER_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FER_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160553 | Colorectum | FAP | Wnt signaling pathway | 104/2622 | 444/18723 | 4.92e-08 | 3.92e-06 | 104 |
GO:00432544 | Colorectum | FAP | regulation of protein-containing complex assembly | 101/2622 | 428/18723 | 5.18e-08 | 4.07e-06 | 101 |
GO:00713753 | Colorectum | FAP | cellular response to peptide hormone stimulus | 75/2622 | 290/18723 | 5.60e-08 | 4.29e-06 | 75 |
GO:00069134 | Colorectum | FAP | nucleocytoplasmic transport | 77/2622 | 301/18723 | 6.15e-08 | 4.54e-06 | 77 |
GO:00511694 | Colorectum | FAP | nuclear transport | 77/2622 | 301/18723 | 6.15e-08 | 4.54e-06 | 77 |
GO:01987383 | Colorectum | FAP | cell-cell signaling by wnt | 104/2622 | 446/18723 | 6.26e-08 | 4.54e-06 | 104 |
GO:19029034 | Colorectum | FAP | regulation of supramolecular fiber organization | 92/2622 | 383/18723 | 8.48e-08 | 5.77e-06 | 92 |
GO:00420604 | Colorectum | FAP | wound healing | 99/2622 | 422/18723 | 9.50e-08 | 6.33e-06 | 99 |
GO:00071603 | Colorectum | FAP | cell-matrix adhesion | 63/2622 | 233/18723 | 1.13e-07 | 7.43e-06 | 63 |
GO:00081544 | Colorectum | FAP | actin polymerization or depolymerization | 60/2622 | 218/18723 | 1.15e-07 | 7.43e-06 | 60 |
GO:00621974 | Colorectum | FAP | cellular response to chemical stress | 83/2622 | 337/18723 | 1.15e-07 | 7.43e-06 | 83 |
GO:00301113 | Colorectum | FAP | regulation of Wnt signaling pathway | 81/2622 | 328/18723 | 1.44e-07 | 9.03e-06 | 81 |
GO:00069794 | Colorectum | FAP | response to oxidative stress | 102/2622 | 446/18723 | 2.29e-07 | 1.33e-05 | 102 |
GO:00322714 | Colorectum | FAP | regulation of protein polymerization | 62/2622 | 233/18723 | 2.64e-07 | 1.53e-05 | 62 |
GO:00328683 | Colorectum | FAP | response to insulin | 68/2622 | 264/18723 | 2.71e-07 | 1.55e-05 | 68 |
GO:19029054 | Colorectum | FAP | positive regulation of supramolecular fiber organization | 57/2622 | 209/18723 | 3.28e-07 | 1.83e-05 | 57 |
GO:00514954 | Colorectum | FAP | positive regulation of cytoskeleton organization | 60/2622 | 226/18723 | 4.45e-07 | 2.37e-05 | 60 |
GO:00300414 | Colorectum | FAP | actin filament polymerization | 53/2622 | 191/18723 | 4.65e-07 | 2.46e-05 | 53 |
GO:00313344 | Colorectum | FAP | positive regulation of protein-containing complex assembly | 62/2622 | 237/18723 | 5.03e-07 | 2.61e-05 | 62 |
GO:00300103 | Colorectum | FAP | establishment of cell polarity | 43/2622 | 143/18723 | 5.22e-07 | 2.66e-05 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FER | SNV | Missense_Mutation | rs763459582 | c.556G>A | p.Val186Ile | p.V186I | P16591 | protein_coding | deleterious(0.05) | probably_damaging(0.97) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2126N>G | p.Glu709Gly | p.E709G | P16591 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FER | SNV | Missense_Mutation | rs533871351 | c.362N>C | p.Ile121Thr | p.I121T | P16591 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1598N>A | p.Thr533Lys | p.T533K | P16591 | protein_coding | tolerated(0.97) | benign(0.045) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.281N>G | p.Ser94Cys | p.S94C | P16591 | protein_coding | deleterious(0.01) | possibly_damaging(0.554) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1484N>A | p.Ser495Tyr | p.S495Y | P16591 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2207G>A | p.Arg736Lys | p.R736K | P16591 | protein_coding | tolerated(0.19) | probably_damaging(0.97) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
FER | deletion | Frame_Shift_Del | novel | c.1357delN | p.Lys453SerfsTer16 | p.K453Sfs*16 | P16591 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
FER | SNV | Missense_Mutation | novel | c.2332C>T | p.Arg778Trp | p.R778W | P16591 | protein_coding | deleterious(0) | benign(0.267) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
FER | SNV | Missense_Mutation | | c.2207N>C | p.Arg736Thr | p.R736T | P16591 | protein_coding | tolerated(0.07) | probably_damaging(0.993) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 328083505 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ALISERTIB | ALISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565817 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | TAMATINIB | R-406 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CENISERTIB | CENISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CYC-116 | CYC-116 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | LINIFANIB | LINIFANIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ENTRECTINIB | ENTRECTINIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CEDIRANIB | CEDIRANIB | |